Thanks Ken,
I take a look at those initial MASH results in
MASH Free For All .

In it, I consider how leronlimab may be combined with GLP-1 Agonists to treat both liver steatosis and fibrosis.

Some things worth mentioning:

Quote:

---

So, these weight loss drugs tirzepatide and semaglutide are only capable of treating just a fraction of the entire MASH population . They are capable of treating the patients with more mild disease ( NAS of 3 or less ) who have not yet developed fibrosis.

---

Quote:

---

For the 7 patients at 350 >950cT1 who lost 68.86 cT1 in 14 weeks time , this was an exceptional result at only 350mg when 28 Placebo gained 27.64 cT1. This loss of nearly 70 cT1 in 14 weeks is nearly equivalent to the loss of 2 stages in the NAS grading system.

---

Quote:

---

So, the point of this is that Eli Lilly, Madrigal Pharmaceuticals and Novo Nordisk all seem capable now of reducing liver steatosis, that is radiographically visualized with the reduction of PDFF, but only Madrigal, with an entire year of treatment at its highest dose of 100mg daily, was able to reduce liver fibrosis by only 1 Stage. In contrast, leronlimab, dosed properly at 350mg was able to reduce liver fibrosis by nearly 2 Stages in only 14 weeks of treatment, only 3.5 months . The question is what would happen if leronlimab was dosed properly for a year?

---

Quote:

---

Even when this trial Surmount-5 completes in November 2024, both drugs are still unable to treat all of MASH to reduce fibrosis . They would have a reducing effect on steatosis, but not on fibrosis. On their own, they will only be able to treat for steatosis and mainly mild to moderate disease . Patients should not get their hopes up thinking their fibrosis will dissipate with these stand alone drugs.

Neither these weight loss drugs nor resmetirom have the capacity to treat liver fibrosis to any significant degree / stage unless they combine with lerolimab . Therefore, if they want to treat the entirety of MASH, including liver fibrosis, they would need to combine with leronlimab. So, what does this mean? It means that since our murine study has an arm that is with and without resmetirom, Madrigal Pharmaceuticals might want to act expeditiously in order to determine how well leronlimab improved results while in combination with resmetirom.

Essentially, Madrigal Pharmaceutical is in a race with Eli Lilly and / or Novo Nordisk and the sooner they get the results from this murine study, the sooner they can decide whether or not to partner up with CytoDyn, because if they don't, then they might lose the opportunity to do so to either Eli Lilly or Novo Nordisk. Whoever partners with CytoDyn wins the MASH race on treating both steatosis and fibrosis and renders the other only a partial treatment of steatosis alone. If Madrigal partners, Madrigal and CytoDyn treat the entirety of MASH while Eli Lilly and Novo Nordisc might treat MASH partially but remain fully engaged in weight loss. If Eli Lilly partners with CytoDyn, then the other two are rendered partial treaters of MASH while Eli Lilly + CytoDyn together treat MASH in entirety. The same is true for Novo Nordisk.

---